Hadhami Ben Turkia
Néji Tebib
Néji Tebib
Mohamed S. Abdelmoula
Amal Ben Chehida
Youssef Hlel
Catherine Caillaud
Héla Sahli
Marie F. Ben Dridi
Hatem Azzouz


Aim: We report through the first Tunisian experience with enzyme replacement therapy, the goals and consensus recommendations for treatment and monitoring of paediatric non neuronopathic Gaucher disease.
Methods: Three children with Gaucher disease undergone enzyme replacement therapy with Cerezyme® for severe visceral and/or bone involvement. Visceral, hematologic, bone, and growth parameters were assessed initially and under treatment.
Results: Two children presented with severe visceral or hematologic picture. One patient had myocardiopathy and primitive portal hypertension and another was diagnosed with cirrhosis related to Gaucher disease. Recurrent avascular necrosis and osteoporosis have justified treatment in another child. All patients received an initial dose of 60U/Kg/2 weeks. We have seen a gradual disappearance of hepatosplenomegaly and a rapid normalisation of hematological parameters in two patients. A resistance to treatment indicated splenectomy in one patient. The improvement in bone mineral density was slower. A significant growth gain was observed in patients with growth retardation. No patient had developed Cerezyme antibodies.
Conclusion: Despite its effectiveness and safety demonstrated in these children, enzyme replacement therapy remains inaccessible because of its cost for emerging countries. The allogeneic bone marrow is an alternative therapy to encourage and to propose precociously for severe paediatric forms of Gaucher disease.


Gaucher disease, Chidhood, Enzyme replacement therapy, Bone marrow transplantation



  1. Beutler E, Grabowski GA. Gaucher disease. In Scriver C, Beaudet A, Valle D, Sly W editors. The metabolic and molecular bases of inherited disease.8th ed. 2001 New york: McGraw-Hill: 3635-68
  2. Germain DP. Gaucher disease: clinical, genetic and therapeutic aspects. Pathol Biol 2004; 52 :343-50
  3. Caubel I, Billette de Villemeur T, Belmatoug N. Comité d'étude du traitement de la maladie de Gaucher. Gaucher's disease in children: first clinical signs, natural course and benefits of enzyme replacement therapy. Arch Pediatr. 2003;10 :681-8
  4. Beutler E, Demina A, Laubscher K et al. The clinical course of treated and untreated Gaucher disease. A study of 45 patients. Blood Cells Mol Dis. 1995;21 :86-108.
  5. Zimran A, Sorge J, Gross E, Kubitz M, West C, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet. 1989; 12; 2:349-52.
  6. Kolodny EH, Ullman MD, Mankin HJ, Raghavan SS, Topol J, Sullivan JL. Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. Prog Clin Biol Res. 1982;95:33-65
  7. Charrow J, Andersson HC, Kaplan P et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr. 2004;144:112-20
  8. Charrow J, Andersson HC, Kaplan P et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease Arch Intern Med. 2000 ;160 :2835-43
  9. Baldellou A, Andria G, Campbell PE et al. Paediatric nonneuronopathic Gaucher disease: recommendations for treatment and monitoring. Eur J Pediatr. 2004; 163:67-75.
  10. Andersson HC, Charrow J, Kaplan P et al. International Collaborative Gaucher Group U.S. Regional Coordinators Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med. 2005; 7: 105-10
  11. Weinreb NJ, Aggio MC, Andersson HC; International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients. Semin Hematol. 2004; 41(4 Suppl 5):15-22
  12. Rosenthal DI, Doppelt SH, Mankin HJ et al. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophagetargeted glucocerebrosidase. Pediatrics. 1995;96:629-37
  13. Schiffmann R, Mankin H, Dambrosia JM et al. Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells, Molecules & Diseases. 2002;28:288-296.
  14. Hermann G, Pastores GM, Abdelwahab IF, Lorberboym AM Gaucher disease: assessment of skeletal involvement and therapeutic responses to enzyme replacement. Skeletal Radiol. 1997;26:687-96.
  15. Elstein D, Hadas-Halpern I, Azuri Y, Abrahamov A, Bar-Ziv Y, Zimran A. Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements. J Ultrasound Med. 1997;16:209-11
  16. Glenn D, Thurston D, Garver P, Beutler E. Comparison of magnetic resonance imaging and ultrasound in evaluating liver size in Gaucher patients Acta Haematol. 1994;92:187-9
  17. Beutler E Lysosomal storage diseases: natural history and ethical and economic aspects Mol Genet Metab. 2006 ;88:208-15
  18. Hoogerbrugge PM, Brouwer OF, Bordigoni P et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995;345 :1398-402
  19. Ringdén O, Groth CG, Erikson A, Granqvist S, MÃ¥nsson JE, Sparrelid E. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation.1995; 59 :864-70